Swissmedic

Swissmedic tauscht sich regelmässig mit Verbänden und Akteuren aus dem Bereich der Medizinprodukte- und In-vitro Diagnostika (IvD) aus. Beim letzten #Roundtable im Februar ging es um: ✅den aktuellen Stand der Regulierung ✅neue Erkenntnisse aus dem Vollzug ✅die Entwicklung und nationale Bedeutung der neuen Datenbank swissdamed ✅Herausforderungen in der Forschung ✅Zusammenarbeit zwischen Laboren und der IvD-Industrie ✅Entwicklung von Qualitätsmanagementsystemen in Spitälern ✅Aus- und Weiterbildungsaktivitäten, z.B. für Spitalpersonal sowie Ausbildungsbedarf im regulatorischen Bereich für Forschende Mehr zum Swissmedic Medtech-Roundtable 👉 https://bit.ly/4iLKkw5 #MedTech #Roundtable #IvD #swissdamed #Swissmedic

DIA 2025 – A Place for Ideas, Exchange & Innovation🚀 ⚡️DIA 2025 in Basel once again brought together experts from more than 50 countries to discuss key developments in regulatory affairs, exchange perspectives, and strengthen professional networks. At the Swissmedic stand, we had the pleasure of welcoming many visitors—engaging in insightful discussions, exploring new ideas, and sharing a moment of refreshment with our signature ginger shot. Thank you to everyone who stopped by, whether for a quick chat, an in-depth exchange, or simply to experience the atmosphere. 💡 Swissmedic was also strongly represented in the conference sessions, with our experts contributing to discussions across a wide range of topics. The dialogue and collaboration during these sessions reflect the shared commitment to continuously evolving regulatory science in a dynamic environment. 🌍🤝 With DIA 2025 now behind us, we take with us valuable insights, new connections, and inspiration for the future. A heartfelt thank you to all speakers, panelists, attendees, and, of course, the dedicated Swissmedic team for making this event a success. We look forward to continuing these conversations and collaborations! #DIA2025 #Swissmedic Nicolas Löffler-Perez , PhD, Julia Djonova, Gabriela Zenhäusern, Christian Schärer, Leonie Rudofsky, Simon Dalla Torre, Iliana Perera, Eveline Trachsel, PhD, eMBA, Sandra Zaugg Kunz, Eiman Atiek, Giulia Paternoster, Jörg Schläpfer, Eva Golet, Daniel Hürlimann

Launch Strategic Plan Access Consortium 2025 – 2028 🚀 Access Consortium has launched its updated strategic plan to strengthen regulatory collaboration and improve access to safe medicines 💊🌍. The focus is on simplifying procedures, enhancing communication, and solidifying collaborative processes. A new cloud-based workspace for joint reviews will further improve efficiency ☁️💻. Key objectives include: 🔗 Strengthening work-sharing initiatives 🔄 Expanding lifecycle approaches 💡 Supporting regulatory innovation 🌐 Enhancing stakeholder engagement The Access Consortium encourages joint applications, particularly those involving all member countries 🌍🤝. For more details, visit: https://lnkd.in/eQPiyiUb

Swissmedic is excited to be part of DIA 2025 in Basel! Come and see us at Stand D11 and experience a shot of innovation! 🚀⚡️ Talk to our specialists, test your skills in our interactive memory game, and explore networking opportunities. We look forward to connecting with you! 👥✨ #Swissmedic #DIA2025 #AShotOfInnovation #Networking #LifeSciences #RegulatoryAffairs

💻Für unsere Abteilung Operational Support Services (OSS) suchen wir eine erfahrene und dynamische Persönlichkeit als Wirtschaftsinformatiker/in (Uni/FH) in der Rolle eines Product Owners (80-100%): https://lnkd.in/e7xCjTjn 📨Wir freuen uns auf Ihre Bewerbung! 🤝 💻Nous recrutons, pour notre division Operational Support Services (OSS), une personne expérimentée et dynamique pour occuper le poste de informaticien/ne de gestion (uni/ES) dans le rôle de Product Owner (80-100%) : https://lnkd.in/eyKaua8h 📨Nous nous réjouissons de recevoir votre candidature !🤝 💻Per la nostra divisione Operational Support Services (OSS) siamo alla ricerca di una persona esperta e dinamica per ricoprire il ruolo di informatico/a di gestione (università/SUP) in qualità di Product Owner (80-100%): https://lnkd.in/esGCzJ28 📨Saremo lieti di ricevere la sua candidatura!🤝 #JoinOurTeam #Wearehiring #ProductOwner

Live Update from Swissmedic's Delegation at the 27th Session of the IMDRF MC in Tokyo ⛩️ 🗻   We're excited to share our highlights from the first two days of the IMDRF Open Session. Swissmedic as an Official Observer is proud to have contributed to both days of the Open Session, discussing key topics and sharing insights on the current and future medical device regulation.   Day 1: At the IMDRF-Industry Joint Workshop Markus Wälti participated in Session 1 on the Strategic Plan, sharing Swissmedic's perspective and suggesting ways for IMDRF to identify new topics and enhance visibility on emerging technologies. 🚀   Day 2 : At the IMDRF Stakeholder Forum, André Breisinger delivered a Regulatory Update, highlighting key developments of the past half year in the Swiss regulatory landscape. His presentation covered: 🛠 Regulatory changes, including the alignment with EU regulation and call for action for manufacturers to check if they have been registered in swissdamed 🔍Insights from recent focus campaigns on post-market surveillance 🎓 Training initiatives to strengthen medical device compliance and safety in hospitals 🤖 Introduction of a natural language processing (NLP)-based risk classification system for incident reports   🤝Swissmedic continues to contribute actively to IMDRF working groups, reinforcing Switzerland’s commitment to advancing global regulatory convergence and reliance.🌍   #Swissmedic #IMDRF #MedicalDevices #RegulatoryAffairs 

#SwissmedicInternational: GLOBAL PARTNERING FOR FASTER ACCESS MARKETING AUTHORISATION FOR GLOBAL HEALTH PRODUCTS (MAGHP) 🌱 Strengthening healthcare in the Global South! Swissmedic’s MAGHP procedure supports the approval of essential medicines for populations in low- and middle-income countries. By collaborating with national regulatory authorities and the World Health Organization, we accelerate access to treatments where they are needed most. This initiative builds regulatory capacity, fosters trust, and contributes to shorter timelines for authorisation of life-saving medicines in the targeted countries. ⚕️🌍 💊 Discover how #MAGHP is making a global impact 🔗 https://lnkd.in/dGEMpN5k